MedTrace Logo

CYP3A4 Activity and Mineral Homeostasis

NCT02019875 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 92

Last updated 2023-04-19

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether changes in the activity of the enzyme CYP3A4 can change the Vitamin D and bone mineral homeostasis.

Conditions

  • Vitamin D and Calcium Homeostasis

Interventions

DRUG

Rifampin

P450 inducer

DRUG

Clarithromycin

CYP3A4 and Pgp inhibitor in both intestine and liiver

OTHER

Grapefruit Juice

CYP3A4 inhibitor in intestine

OTHER

Placebo

Sponsors & Collaborators

Principal Investigators

  • Kenneth Thummel, Ph.D. · University of Washington

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2020-12-31
Completion
2020-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02019875 on ClinicalTrials.gov